Tag: $Novo Nordisk

Shares of Novo Nordisk on Monday fell to a four-year low after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal.

Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.

Shares of Metsera, fell nearly 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer, to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market.

Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.

Novo Nordisk A/S (NYSE:NVO) stock rose 2.8% in Monday’s premarket trading after the European Medicines Agency approved an update to the Rybelsus label to include cardiovascular benefits for patients with type 2 diabetes.

Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce.

Novo Nordisk’s (NOVO.B) Wegovy cut the risk of heart attacks, stroke and death by more than Eli Lilly’s (LLY) weight-loss drug Zepbound, a new study found.

Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk.

Wegovy-maker Novo Nordisk (NOVOb.CO), has implemented a global hiring freeze covering job roles that are not critical for its business, the company said on Wednesday.

Shares of  Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease.

Novo Nordisk(NVO) vowed to cut costs Wednesday amid intensifying competition and a cratering stock price as it reported second-quarter earnings.

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its blockbuster Wegovy obesity drug in the key U.S. market.

 Eli Lilly (LLY.N), said on Thursday that India’s drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk’s recently launched Wegovy.

Shares in Novo Nordisk (NYSE:NVO) fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly (NYSE:LLY)’s pipeline.

Hims & Hers Health (NYSE:HIMS) stock plunged 20% after pharmaceutical giant Novo Nordisk (NYSE:NVO) announced it would terminate its collaboration with the telehealth company over the sale of weight loss drugs.

The European Medicines Agency’s safety committee has concluded that the use of Novo Nordisk’s (NOVOb.CO), popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Eli Lilly (LLY.N),  said on Sunday its drug Zepbound was superior to Novo Nordisk’s (NOVOb.CO),  Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.